You just read:

Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients

News provided by

Medivir AB

20 May, 2011, 07:15 BST